|
See related Tasigna cap[泰息安 膠囊] information |
|
|
|
製造商 |
Novartis |
|
代理/經銷商 |
Novartis |
|
成份 |
Nilotinib |
|
適應症 |
Treatment of chronic phase & accelerated phase Philadelphia chromosome +ve chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib. |
|
用量 |
400 mg bid at 12-hr intervals. |
|
過量 |
View Tasigna[泰息安] overdosage for action to be taken in the event of an overdose. |
|
用法 |
Should be taken on an empty stomach (Avoid food at least 2 hr before and at least 1 hr after a dose. Swallow whole, do not chew/crush. Avoid grapefruit products.). |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Hypokalemia, hypomagnesemia, or long QT syndrome. Pregnancy. |
|
注意事項 |
Myelosuppression. Patients with QT prolongation. Hepatic impairment. Electrolyte abnormalities must be corrected prior therapy. History of pancreatitis. Galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption. Complete blood counts should be performed every 2 weeks for the 1st 2 months & then monthly thereafter. Lactation. |
|
不良反應 |
Rash, pruritis, nausea, fatigue, headache, constipation, diarrhea & vomiting. Thrombocytopenia & neutropenia, pneumonia, leukopenia, intracranial hemorrhage, elevated lipase & pyrexia. Sudden deaths & QT prolongation were reported.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Concomitant use of strong CYP3A4 inhibitors (eg. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) & strong CYP3A4 inducers (eg. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarb) should be avoided. Grapefruit products. St. John's Wort. Drugs that prolongs QT. Drugs that Inhibit P-glycoprotein (Pgp, ABCB1).
View more drug interactions with Tasigna[泰息安] |
|
儲存 |
View Tasigna[泰息安] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Tasigna[泰息安] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Tasigna[泰息安] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Novartis
|
|
|
|
